Alexander, M S
Gasperini, M J
Tsai, P T
Gibbs, D E
Spinazzola, J M
Marshall, J L
Feyder, M J
Pletcher, M T
Chekler, E L P
Morris, C A
Sahin, M
Harms, J F
Schmidt, C J
Kleiman, R J
Kunkel, L M
Article History
Received: 7 July 2016
Accepted: 18 July 2016
First Online: 27 September 2016
Competing interests
: LMK is a consultant for Pfizer, Summit Corporation PLC and Sarepta Therapeutics for muscle disease drug therapies. MTP, CAM, all hold equity in Pfizer. MTP is a current employee of Autism Speaks. RJK is a consultant for Ironwood Pharmaceuticals. CJS, JFH and ELPC are employees of Pfizer. MS is on the Scientific Advisory Board of Sage Therapeutics and has received research support from Novartis and Shire. The remaining authors declare no conflict of interest.